Jefferies on Inhibikase Therapeutics Inc (IKT): 'the stock at $200-250M cap is inexpensive'
Tweet Send to a Friend
Jefferies analyst Dennis Ding reiterated a Buy rating and $8.00 price target on Inhibikase Therapeutics Inc (NASDAQ: IKT).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
